Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?

COPD exacerbations are associated with considerable morbidity and mortality. In a well-designed RCT, Schenk and colleagues show that simvastatin reduces COPD exacerbations by 23% relative to placebo in patients optimised on preventive inhaler therapy.https://bit.ly/2NAFM2v